Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
421 studies found for:    "Hemophilia"
Show Display Options
Rank Status Study
21 Completed Project to Update the Study of Congenital Haemophilia in Spain
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Other: No treatment given
22 Completed
Has Results
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Interventions: Drug: eptacog alfa (activated);   Drug: vatreptacog alfa (activated)
23 Completed Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
Conditions: Hemophilia A;   Hemophilia B
Intervention:
24 Active, not recruiting Hemophilia B Gene Therapy - Spark
Condition: Hemophilia B
Intervention: Biological: AAV8-hFIX19
25 Active, not recruiting An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
Conditions: Hemophilia A;   Hemophilia B;   Factor VIII Deficiency;   Factor IX Deficiency
Intervention: Device: Accelerometer
26 Completed Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
27 Completed The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs
Conditions: Hemophilia A;   Hemophilia B
Interventions: Behavioral: Counseling;   Behavioral: Control
28 Completed A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
Conditions: Haemophilia A;   Haemophilia B
Intervention:
29 Completed Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
30 Completed Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
Conditions: Hemophilia A;   Hemophilia B
Interventions: Biological: ADVATE (Antihemophilic Factor [Recombinant]);   Biological: RIXUBIS (Coagulation Factor IX [Recombinant])
31 Recruiting A Single Escalating Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: BAY1093884
32 Completed Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
33 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
34 Completed Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: NNC 0128-0000-2011
35 Completed Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: BAY Factor VII (BAY86-6150);   Drug: Placebo
36 Completed Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B;   Healthy
Interventions: Drug: NNC 0172-0000-2021;   Drug: placebo
37 Completed Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
38 Completed Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII, long acting
39 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
40 Completed Trial of NovoSeven® in Haemophilia - Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Drug: Feiba VH

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years